IDH1 Mutant Brain Tumor Vaccine Shows Remarkable 8-Year Survival in Phase 1 Trial
A neoantigen peptide vaccine targeting IDH1-R132H mutation doubled median survival in grade IV astrocytoma patients vs. historical benchmarks.
Summary
A first-in-human phase 1 trial tested a personalized peptide vaccine targeting the IDH1-R132H mutation — a clonal driver found in certain brain tumors — in 33 patients with newly diagnosed grade III and IV astrocytomas. The final 8-year analysis revealed striking long-term outcomes: median overall survival for grade IV patients reached 106 months, compared to a historical range of 31–56 months. Patients who mounted sustained antibody responses to the vaccine fared best clinically. Vaccine-induced T cells were detected in brain lesions of patients who experienced pseudoprogression, a positive immune sign, but were absent in patients with early disease progression. These results strongly support advancing the IDH1 vaccine into a randomized phase 2 trial.
Detailed Summary
Brain tumors harboring the IDH1-R132H mutation represent a genetically defined subset of gliomas with a shared, targetable neoantigen. Because this mutation is clonal — present in every tumor cell — it offers an ideal target for a neoantigen-based cancer vaccine that could prime the immune system to recognize and attack tumor cells specifically.
The NOA16 trial enrolled 33 patients with newly diagnosed grade III and IV IDH1-R132H-positive astrocytomas across multiple German centers. Participants received an IDH1-R132H peptide vaccine integrated into standard-of-care treatment. The trial previously met its primary endpoints of safety and immunogenicity; this report presents the long-term clinical and immunological follow-up data as secondary and translational endpoints.
At 8 years, the progression-free survival rate was 42% and overall survival (OS) rate was 66%. Most strikingly, median OS for grade IV astrocytoma patients was 106.1 months — nearly double the published historical median of 31.6–56.4 months in comparable populations. Patients who maintained sustained antibody responses to IDH1-R132H showed the most favorable long-term clinical outcomes, suggesting immunological durability is a key driver of benefit.
On a mechanistic level, vaccine-induced T cells were identified within brain lesions in patients who experienced pseudoprogression — an imaging pattern that can mimic tumor growth but reflects immune activity. Conversely, no vaccine-induced T cells were found in patients with early progressive disease, linking immune response quality to clinical outcome.
These findings provide compelling rationale for a randomized phase 2 trial (NCT02454634) in newly diagnosed grade 3 and 4 IDH-mutant astrocytomas per 2021 WHO classification. While the single-arm design limits causal conclusions, the magnitude of the survival signal is notable and positions IDH1-vac as a promising precision immunotherapy approach for this patient population.
Key Findings
- Median overall survival for grade IV astrocytoma patients was 106.1 months vs. 31.6–56.4 months historically.
- 8-year progression-free and overall survival rates were 42% and 66%, respectively.
- Sustained antibody responses to IDH1-R132H correlated with better long-term clinical outcomes.
- Vaccine-induced T cells were detected in brain lesions of pseudoprogression cases, confirming immune engagement.
- Results support advancement to a randomized phase 2 trial in IDH-mutant astrocytoma patients.
Methodology
NOA16 was a multicenter, single-arm, open-label, first-in-human phase 1 trial enrolling 33 patients with newly diagnosed IDH1-R132H-positive grade III and IV astrocytomas. Participants received an IDH1-R132H peptide vaccine alongside standard of care. This report is the final analysis covering 8-year clinical and immunological follow-up as secondary and translational endpoints.
Study Limitations
This is a single-arm, uncontrolled phase 1 trial with only 33 participants, making direct causal attribution of survival benefit to the vaccine difficult. Historical comparator data introduces confounding variability. The summary is based on the abstract only, as the full text was not available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: